FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034782018> ?p ?o ?g. }

• W2034782018 endingPage "1924" @default.
• W2034782018 startingPage "1919" @default.
• W2034782018 abstract "In this phase 3 trial we assessed the efficacy of solifenacin 5 mg and 10 mg daily in patients with symptoms related to overactive bladder. In addition, we assessed the safety and acceptability of solifenacin.The study was a multicenter, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to 12-week once daily treatment with solifenacin 5 mg, solifenacin 10 mg or placebo. The primary efficacy variable was changed from baseline to study end point in mean number of micturitions per 24 hours. Secondary efficacy variables included changes from baseline in mean number of urgency, nocturia and incontinence episodes per 24 hours, and mean volume voided per micturition.Compared with changes obtained with placebo (-1.59), micturitions per 24 hours were statistically significantly decreased with solifenacin 5 mg (-2.37, p = 0.0018) and solifenacin 10 mg (-2.81, p = 0.0001). A statistically significant decrease was observed in the number of incontinence episodes with both solifenacin doses (5 mg, p = 0.002 and 10 mg, p = 0.016). This effect was also seen for episodes of urge incontinence (5 mg, p = 0.014 and 10 mg, p = 0.042). Of patients reporting incontinence at baseline, fully 50% achieved continence after treatment with solifenacin. Episodes of nocturia were statistically significantly decreased in patients treated with solifenacin 10 mg (-0.71, -38.5%) versus placebo (-0.52, -16.4%, p = 0.036). Episodes of urgency were statistically significantly reduced with solifenacin 5 mg (-2.84, -51%, p = 0.003) and solifenacin 10 mg (-2.90, -52%, p = 0.002). Mean volume voided per micturition was statistically significantly increased with both solifenacin doses (p = 0.0001). Treatment with solifenacin was well tolerated. Dry mouth, mostly mild in severity, was reported in 7.7% of patients receiving solifenacin 5 mg and 23% receiving solifenacin 10 mg (vs 2.3% with placebo).In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence. Solifenacin 10 mg also decreased the frequency of nocturia. Solifenacin therapy was associated with a favorable tolerability profile and a low incidence of dry mouth, especially at the 5 mg starting dose." @default.
• W2034782018 created "2016-06-24" @default.
• W2034782018 creator A5014232528 @default.
• W2034782018 creator A5019529291 @default.
• W2034782018 creator A5027564635 @default.
• W2034782018 creator A5031776828 @default.
• W2034782018 creator A5049416260 @default.
• W2034782018 creator A5065452127 @default.
• W2034782018 creator A5074502923 @default.
• W2034782018 creator A5081498366 @default.
• W2034782018 date "2004-11-01" @default.
• W2034782018 modified "2023-10-01" @default.
• W2034782018 title "RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER" @default.
• W2034782018 cites W1968860914 @default.
• W2034782018 cites W1978083855 @default.
• W2034782018 cites W1985245928 @default.
• W2034782018 cites W1986143238 @default.
• W2034782018 cites W1993384839 @default.
• W2034782018 cites W2019362433 @default.
• W2034782018 cites W2026599479 @default.
• W2034782018 cites W2052790257 @default.
• W2034782018 cites W2059946745 @default.
• W2034782018 cites W2092749677 @default.
• W2034782018 cites W2126587119 @default.
• W2034782018 cites W2134928141 @default.
• W2034782018 cites W2148524234 @default.
• W2034782018 cites W2153390278 @default.
• W2034782018 doi "https://doi.org/10.1097/01.ju.0000140729.07840.16" @default.
• W2034782018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15540755" @default.
• W2034782018 hasPublicationYear "2004" @default.
• W2034782018 type Work @default.
• W2034782018 sameAs 2034782018 @default.
• W2034782018 citedByCount "289" @default.
• W2034782018 countsByYear W20347820182012 @default.
• W2034782018 countsByYear W20347820182013 @default.
• W2034782018 countsByYear W20347820182014 @default.
• W2034782018 countsByYear W20347820182015 @default.
• W2034782018 countsByYear W20347820182016 @default.
• W2034782018 countsByYear W20347820182017 @default.
• W2034782018 countsByYear W20347820182018 @default.
• W2034782018 countsByYear W20347820182019 @default.
• W2034782018 countsByYear W20347820182020 @default.
• W2034782018 countsByYear W20347820182021 @default.
• W2034782018 countsByYear W20347820182022 @default.
• W2034782018 countsByYear W20347820182023 @default.
• W2034782018 crossrefType "journal-article" @default.
• W2034782018 hasAuthorship W2034782018A5014232528 @default.
• W2034782018 hasAuthorship W2034782018A5019529291 @default.
• W2034782018 hasAuthorship W2034782018A5027564635 @default.
• W2034782018 hasAuthorship W2034782018A5031776828 @default.
• W2034782018 hasAuthorship W2034782018A5049416260 @default.
• W2034782018 hasAuthorship W2034782018A5065452127 @default.
• W2034782018 hasAuthorship W2034782018A5074502923 @default.
• W2034782018 hasAuthorship W2034782018A5081498366 @default.
• W2034782018 hasConcept C126322002 @default.
• W2034782018 hasConcept C126894567 @default.
• W2034782018 hasConcept C142724271 @default.
• W2034782018 hasConcept C168563851 @default.
• W2034782018 hasConcept C175768497 @default.
• W2034782018 hasConcept C204787440 @default.
• W2034782018 hasConcept C27081682 @default.
• W2034782018 hasConcept C2777333188 @default.
• W2034782018 hasConcept C2778941218 @default.
• W2034782018 hasConcept C2779502394 @default.
• W2034782018 hasConcept C71924100 @default.
• W2034782018 hasConcept C77411442 @default.
• W2034782018 hasConceptScore W2034782018C126322002 @default.
• W2034782018 hasConceptScore W2034782018C126894567 @default.
• W2034782018 hasConceptScore W2034782018C142724271 @default.
• W2034782018 hasConceptScore W2034782018C168563851 @default.
• W2034782018 hasConceptScore W2034782018C175768497 @default.
• W2034782018 hasConceptScore W2034782018C204787440 @default.
• W2034782018 hasConceptScore W2034782018C27081682 @default.
• W2034782018 hasConceptScore W2034782018C2777333188 @default.
• W2034782018 hasConceptScore W2034782018C2778941218 @default.
• W2034782018 hasConceptScore W2034782018C2779502394 @default.
• W2034782018 hasConceptScore W2034782018C71924100 @default.
• W2034782018 hasConceptScore W2034782018C77411442 @default.
• W2034782018 hasIssue "5" @default.
• W2034782018 hasLocation W20347820181 @default.
• W2034782018 hasLocation W20347820182 @default.
• W2034782018 hasOpenAccess W2034782018 @default.
• W2034782018 hasPrimaryLocation W20347820181 @default.
• W2034782018 hasRelatedWork W2364382203 @default.
• W2034782018 hasRelatedWork W2389841854 @default.
• W2034782018 hasRelatedWork W2605515582 @default.
• W2034782018 hasRelatedWork W2606250578 @default.
• W2034782018 hasRelatedWork W3029816848 @default.
• W2034782018 hasRelatedWork W3031313022 @default.
• W2034782018 hasRelatedWork W3031795644 @default.
• W2034782018 hasRelatedWork W3112491623 @default.
• W2034782018 hasRelatedWork W3212015874 @default.
• W2034782018 hasRelatedWork W4306316488 @default.
• W2034782018 hasVolume "172" @default.
• W2034782018 isParatext "false" @default.
• W2034782018 isRetracted "false" @default.
• W2034782018 magId "2034782018" @default.
• W2034782018 workType "article" @default.